Key statistics
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | -- |
| Low | -- |
| Bid | -- |
| Offer | -- |
| Previous close | -- |
| Average volume | -- |
|---|---|
| Shares outstanding | 61.88m |
| Free float | 61.88m |
| P/E (TTM) | 36.56 |
| Market cap | 44.43bn EUR |
| EPS (TTM) | 19.64 EUR |
--
More ▼
Announcements
- argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
- argenx Highlights 2026 Strategic Priorities
- argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
- argenx Announces Leadership Transition Marking Next Evolution of Growth
- argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
- argenx Announces Results of Extraordinary General Meeting of Shareholders
- argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
- argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
- argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
- argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
More ▼
